Kairos Pharma, Ltd. (KAPA)
Kairos Pharma, Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Los Angeles, CA, US. The stock last traded at $1.72, down 2.82% on the session, giving a market capitalisation of $5.3M. On trailing twelve-month figures it carries a trailing P/E of -0.89, a net margin of 0.0%. Its beta of 1.48 implies it has historically moved more than the broad market.
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
Kairos Pharma, Ltd. is most often compared with the following Healthcare names: